The lawsuit claims that the two companies, Novo Nordisk and Eli Lilly, knew of the association between the use of GLP-1 receptor agonists and the risk of developing severe gastrointestinal issues, including gastroparesis and gastroenteritis. Their failure to disclose information that they possessed regarding the association between the use of GLP-1 receptor agonists and the risk of developing severe gastrointestinal issues, including gastroparesis and gastroenteritis, rendered the warnings for this medication inadequate, it continues
MHRA-approved options include orlistat (prescription and over the counter), semaglutide (Wegovy, supported by NICE TA875), and liraglutide (Saxenda, supported by NICE TA664)
The most upheld revolves around cardiac metabolism [47]
Always follow your providers specific instructions they may tailor timing based on your individual health and treatment goals
Vitamin B12 injections are a common and effective treatment for B12 deficiency